|
1
|
World Health Organization. International
Agency for Research on Cancer: World Cancer Report. IARC Press;
Lyon: 2003
|
|
2
|
Amant F, Moerman P, Neven P, Timmerman D,
Van Limbergen E and Vergote I: Endometrial cancer. Lancet.
366:491–505. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Engelsen IB, Akslen LA and Salvesen HB:
Biologic markers in endometrial cancer treatment. APMIS.
117:693–707. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Vogelstein B and Kinzler KW: Cancer genes
and the pathways they control. Nat Med. 10:789–799. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Enomoto T, Inoue M, Perantoni AO, Terakawa
N, Tanizawa O and Rice JM: K-ras activation in neoplasms of the
human female reproductive tract. Cancer Res. 50:6139–6145.
1990.PubMed/NCBI
|
|
6
|
Caduff RF, Johnston CM and Frank TS:
Mutations of the Ki-ras oncogene in carcinoma of the endometrium.
Am J Pathol. 146:182–188. 1995.PubMed/NCBI
|
|
7
|
Mammas IN, Zafiropoulos A and Spandidos
DA: Involvement of the ras genes in female genital tract. Int J
Oncol. 26:1241–1255. 2005.PubMed/NCBI
|
|
8
|
Cully M, You H, Levine AJ and Mak TW:
Beyond PTEN mutations: the PI3K pathway as an integrator of
multiple inputs during tumorigenesis. Nat Rev Cancer. 6:184–192.
2006. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Slomovitz BM, Broaddus RR, Burke TW,
Sneige N, Soliman PT and Wu W: Her-2/neu overexpression and
amplification in uterine papillary serous carcinoma. J Clin Oncol.
22:3126–3132. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Berchuck A, Rodriguez G, Kinney RB, Soper
JT, Dodge RK and Clarke-Pearson DL: Overexpression of HER-2/neu in
endometrial cancer is associated with advanced stage disease. Am J
Obstet Gynecol. 164:15–21. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Morrison C, Zanagnolo V, Ramirez N, Cohn
DE, Kelbick N and Copeland L: HER-2 is an independent prognostic
factor in endometrial cancer: association with outcome in a large
cohort of surgically staged patients. J Clin Oncol. 24:2376–2385.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Oda K, Stokoe D, Taketani Y and McCormick
F: High frequency of coexistent mutations of PIK3CA and PTEN genes
in endometrial carcinoma. Cancer Res. 65:10669–10673. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Salvesen HB, Carter SL, Mannelqvist M,
Dutt A, Stefansson IM and Getz G: Integrated genomic profiling of
endometrial carcinoma associates aggressive tumors with indicators
of PI3 kinase activation. Proc Natl Acad Sci USA. 106:4834–4839.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Soufla G, Sifakis S and Spandidos DA: FGF2
transcript levels are positively correlated with EFG and IGF-1 in
the malignant endometrium. Cancer Lett. 259:146–155. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Dutt A, Salvesen HB, Chen TH, Ramos AH,
Onofrio RC and Hatton C: Drug-sensitive FGFR2 mutations in
endometrial carcinoma. Proc Natl Acad Sci USA. 105:8713–8717. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Tamura M, Gu J, Matsumoto K, Aota S,
Parsons R and Yamada KM: Inhibition of cell migration, spreading,
and focal adhesions by tumor suppressor PTEN. Science. 280:614–617.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Salvesen HB, MacDonald N, Ryan A, Jacobs
IJ, Lynch ED and Akslen LA: PTEN methylation is associated with
advanced stage and microsatellite instability in endometrial
carcinoma. Int J Cancer. 91:22–26. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Salvesen HB, Stefansson I, Kretzschmar EI,
Gruber P, MacDonald ND and Ryan A: Significance of PTEN alterations
in endometrial carcinoma: a population-based study of mutations,
promoter methylation and PTEN protein expression. Int J Oncol.
25:1615–1623. 2004.PubMed/NCBI
|
|
19
|
Maxwell GL, Risinger JI, Gumbs C, Shaw H,
Bentley RC and Barrett JC: Mutation of the PTEN tumor suppressor
gene in endometrial hyperplasias. Cancer Res. 58:2500–2503.
1998.PubMed/NCBI
|
|
20
|
Prat J, Gallardo A, Cuatrecasas M and
Catasus L: Endometrial carcinoma: pathology and genetics.
Pathology. 39:72–87. 2007. View Article : Google Scholar
|
|
21
|
Vogelstein B and Kinzler KW: p53 function
and dysfunction. Cell. 70:523–526. 1992. View Article : Google Scholar
|
|
22
|
Soong R, Robbins PD, Dix BR, Grieu F, Lim
B and Knowles S: Concordance between p53 protein overexpression and
gene mutation in a large series of common human carcinomas. Hum
Pathol. 27:1050–1055. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Risinger JI, Dent GA, Ignar-Trowbridge D,
McLachlan JA, Tsao MS and Senterman M: p53 gene mutations in human
endometrial carcinoma. Mol Carcinog. 5:250–253. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kihana T, Hamada K, Inoue Y, Yano N,
Iketani H and Murao S: Mutation and allelic loss of the p53 gene in
endometrial carcinoma. Cancer. 76:72–78. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Soong R, Knowles S, Williams KE, Hammond
IG, Wysocki SJ and Iacopetta BJ: Overexpression of p53 protein is
an independent prognostic indicator in human endometrial carcinoma.
Br J Cancer. 74:562–567. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Pisani AL, Barbuto DA, Chen D, Ramos L,
Lagasse LD and Karlan BY: HER-2/neu, p53, and DNA analyses as
prognosticators for survival in endometrial carcinoma. Obstet
Gynecol. 85:729–734. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lax SF, Kendall B, Tashiro H, Slebos RJ
and Hedrick L: The frequency of p53, K-ras mutations, and
microsatellite instability differs in uterine endometrioid and
serous carcinoma: evidence of distinct molecular genetic pathways.
Cancer. 88:814–824. 2000. View Article : Google Scholar
|
|
28
|
Nuovo GJ, Plaia TW, Belinsky SA, Baylin SB
and Herman JG: In situ detection of the hypermethylation-induced
inactivation of the p16 gene as an early event in oncogenesis. Proc
Natl Acad Sci USA. 96:12754–12759. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Nakashima R, Fujita M, Enomoto T, Haba T,
Yoshino K and Wada H: Alteration of p16 and p15 genes in human
uterine tumours. Br J Cancer. 80:458–467. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Salvesen HB, Das S and Akslen LA: Loss of
nuclear p16 protein expression is not associated with promoter
methylation but defines a subgroup of aggressive endometrial
carcinomas with poor prognosis. Clin Cancer Res. 6:153–159.
2000.PubMed/NCBI
|
|
31
|
Milde-Langosch K, Riethdorf L, Bamberger
AM and Löning T: P16/MTS1 and pRB expression in endometrial
carcinomas. Virchows Arch. 434:23–28. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ionov Y, Peinado MA, Malkhosyan S, Shibata
D and Perucho M: Ubiquitous somatic mutations in simple repeated
sequences reveal a new mechanism for colonic carcinogenesis.
Nature. 363:558–561. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Lynch HT, Smyrk T and Lynch JF: Overview
of natural history, pathology, molecular genetics and management of
HNPCC (Lynch Syndrome). Int J Cancer. 69:38–43. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Caduff RF, Johnston CM, Svoboda-Newman SM,
Poy EL, Merajver SD and Frank TS: Clinical and pathological
significance of microsatellite instability in sporadic endometrial
carcinoma. Am J Pathol. 148:1671–1678. 1996.PubMed/NCBI
|
|
35
|
Esteller M, Levine R, Baylin SB, Ellenson
LH and Herman JG: MLH1 promoter hypermethylation is associated with
the microsatellite instability phenotype in sporadic endometrial
carcinomas. Oncogene. 17:2413–2417. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Catasus L, Machin P, Matias-Guiu X and
Prat J: Microsatellite instability in endometrial carcinomas:
clinicopathologic correlations in a series of 42 cases. Hum Pathol.
29:1160–1164. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Arvanitis DA, Angelakis E, Koumantakis EE
and Spandidos DA: Allelic imbalance in hMLH1 or BRCA2 loci
associated with response of cervical and endometrial cancer to
radiotherapy. Int J Mol Med. 10:55–63. 2002.PubMed/NCBI
|
|
38
|
Horree N, Van Diest PJ, Sie-Go DM and
Heintz AP: The invasive front in endometrial carcinoma: higher
proliferation and associated derailment of cell cycle regulators.
Hum Pathol. 38:1232–1238. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Sakuragi N, Salah-eldin AE, Watari H, Itoh
T, Inoue S and Moriuchi T: Bax, Bcl-2, and p53 expression in
endometrial cancer. Gynecol Oncol. 86:288–296. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Ohkouchi T, Sakuragi N, Watari H, Nomura
E, Todo Y and Yamada H: Prognostic significance of Bcl-2, p53
overexpression, and lymph node metastasis in surgically staged
endometrial carcinoma. Am J Obstet Gynecol. 187:353–359. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Ito K, Utsunomiya H, Yaegashi N and Sasano
H: Biological roles of estrogen and progesterone in human
endometrial carcinoma - new developments in potential endocrine
therapy for endometrial cancer. Endocr J. 54:667–679. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
McDonnell DP and Norris JD: Connections
and regulation of the human estrogen receptor. Science.
296:1642–1644. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Shang Y: Molecular mechanisms of oestrogen
and SERMs in endometrial carcinogenesis. Nat Rev Cancer. 6:360–368.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
van der Putten HW, Baak JP, Koenders TJ,
Kurver PH, Stolk HG and Stolte LA: Prognostic value of quantitative
pathologic features and DNA content in individual patients with
stage I endometrial adenocarcinoma. Cancer. 63:1378–1387.
1989.PubMed/NCBI
|
|
45
|
Susini T, Amunni G, Molino C, Carriero C,
Rapi S and Branconi F: Ten-year results of a prospective study on
the prognostic role of ploidy in endometrial carcinoma: DNA
aneuploidy identifies high-risk cases among the so-called
‘low-risk’ patients with well and moderately differentiated tumors.
Cancer. 109:882–890. 2007.PubMed/NCBI
|
|
46
|
Risinger JI, Maxwell GL, Chandramouli GV,
et al: Microarray analysis reveals distinct gene expression
profiles among different histologic subtypes of endometrial cancer.
Cancer Res. 63:72–87. 2003.
|
|
47
|
Planagumà J, Díaz-Fuertes M, Gil-Moreno A,
et al: A differential gene expression profile reveals
overexpression of RUNX1/AML1 in invasive endometrioid carcinoma.
Cancer Res. 64:8846–8853. 2004.PubMed/NCBI
|
|
48
|
Colas E, Perez C, Cabrera S, et al:
Molecular markers of endometrial carcinoma detected in uterine
aspirates. Int J Cancer. 129:2435–2444. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Prat J: Prognostic parameters of
endometrial carcinoma. Hum Pathol. 35:649–662. 2004. View Article : Google Scholar
|
|
50
|
Yamazawa K, Seki K, Matsui H, Kihara M and
Sekiya S: Prognostic factors in young women with endometrial
carcinoma: a report of 20 cases and review of literature. Int J
Gynecol Cancer. 10:212–222. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Singh M, Zaino RJ, Filiaci VJ and Leslie
KK: Relationship of estrogen and progesterone receptors to clinical
outcome in metastatic endometrial carcinoma: a Gynecologic Oncology
Group Study. Gynecol Oncol. 106:325–333. 2007. View Article : Google Scholar
|
|
52
|
Slomovitz BM, Broaddus RR, Burke TW,
Sneige N, Soliman PT and Wu W: Her-2/neu overexpression and
amplification in uterine papillary serous carcinoma. J Clin Oncol.
22:3126–3132. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Salvesen HB, Iversen OE and Akslen LA:
Prognostic significance of angiogenesis and Ki-67, p53 and p21
expression: a population-based endometrial carcinoma study. J Clin
Oncol. 17:1382–1390. 1999.PubMed/NCBI
|
|
54
|
Salvesen HB, Stefansson I, Kalvenes MB,
Das S and Akslen LA: Loss of PTEN expression is associated with
metastatic disease in patients with endometrial carcinoma. Cancer.
94:2185–2191. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Nordström B, Strang P, Bergström R,
Nilsson S and Tribukait B: A comparison of proliferation markers
and their prognostic value for women with endometrial carcinoma.
Cancer. 78:1942–1951. 1996.PubMed/NCBI
|
|
56
|
Al Kushi A, Lim P, Quino-Parsons C and
Gilks CB: Markers of proliferative activity are predictors of
patient outcome for low-grade endometrioid adenocarcinoma but not
papillary serous carcinoma of endometrium. Mod Pathol. 15:365–371.
2002.PubMed/NCBI
|
